<DOC>
	<DOCNO>NCT02245503</DOCNO>
	<brief_summary>The objective post marketing surveillance study document comorbidity comedication prescription ALNA® ( Tamsulosin ) patient BPH ( Benign Prostatic Hyperplasia ) .</brief_summary>
	<brief_title>Observational Study ALNA® ( Tamsulosin ) Patients With Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Indication treatment ALNA accord summary product characteristic ( SPC ) Patients fulfil one general specific contraindication list ALNA SPC , particularly patient know hypersensitivity tamsulosin hydrochloride ingredient product , orthostatic dysregulation severe liver insufficiency include study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>